324 related items for PubMed ID: 37477752
1. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Ohyama R, Fujinaga S, Sakuraya K, Hirano D, Ito S.
Clin Exp Nephrol; 2023 Oct; 27(10):865-872. PubMed ID: 37477752
[Abstract] [Full Text] [Related]
2. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T.
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[Abstract] [Full Text] [Related]
3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
[Abstract] [Full Text] [Related]
4. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
Pediatr Nephrol; 2019 Nov 01; 34(11):2417-2421. PubMed ID: 31435725
[Abstract] [Full Text] [Related]
5. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T.
Clin Nephrol; 2016 Jun 01; 85(6):340-5. PubMed ID: 27125626
[Abstract] [Full Text] [Related]
6. Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.
Parmentier C, Delbet JD, Decramer S, Boyer O, Hogan J, Ulinski T.
Pediatr Nephrol; 2020 Mar 01; 35(3):455-462. PubMed ID: 31705306
[Abstract] [Full Text] [Related]
7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Pediatr Nephrol; 2017 Nov 01; 32(11):2071-2078. PubMed ID: 28664242
[Abstract] [Full Text] [Related]
8. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.
Pediatr Nephrol; 2013 Feb 01; 28(2):257-64. PubMed ID: 23052656
[Abstract] [Full Text] [Related]
9. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K.
Pediatr Nephrol; 2019 Feb 01; 34(2):353-357. PubMed ID: 30426219
[Abstract] [Full Text] [Related]
10. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, Mekahli D.
Acta Clin Belg; 2017 Jun 01; 72(3):147-155. PubMed ID: 27409338
[Abstract] [Full Text] [Related]
11. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S.
Pediatr Nephrol; 2016 Jan 01; 31(1):89-95. PubMed ID: 26341251
[Abstract] [Full Text] [Related]
12. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
Zhi YZ, Cao L, Ying DJ, Dou WJ, Gu R, Zhang JJ.
Zhonghua Yi Xue Za Zhi; 2024 Feb 06; 104(6):433-439. PubMed ID: 38326055
[Abstract] [Full Text] [Related]
13. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
Pediatr Nephrol; 2011 Oct 06; 26(10):1823-8. PubMed ID: 21556716
[Abstract] [Full Text] [Related]
14. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
Taguchi S, Ohtake T, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S.
Clin Exp Nephrol; 2020 Dec 06; 24(12):1132-1139. PubMed ID: 32761467
[Abstract] [Full Text] [Related]
15. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T.
Nephrol Dial Transplant; 2012 Mar 06; 27(3):1083-9. PubMed ID: 21810762
[Abstract] [Full Text] [Related]
16. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K.
Am J Nephrol; 2013 Mar 06; 38(6):483-8. PubMed ID: 24296765
[Abstract] [Full Text] [Related]
17. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
Choi N, Min J, Kim JH, Kang HG, Ahn YH.
Pediatr Nephrol; 2024 Mar 06; 39(3):771-780. PubMed ID: 37682369
[Abstract] [Full Text] [Related]
18. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG.
Medicine (Baltimore); 2018 Nov 06; 97(46):e13157. PubMed ID: 30431588
[Abstract] [Full Text] [Related]
19. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
Fujimoto K, Kagaya Y, Kumano S, Fujii A, Tsuruyama Y, Matsuura T, Yamazaki K, Nomura K, Okada K, Okino K, Adachi H, Furuichi K, Yokoyama H.
Clin Nephrol; 2021 Jan 06; 95(1):29-36. PubMed ID: 33074094
[Abstract] [Full Text] [Related]
20. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
